Drug improves metastatic prostate cancer survival

​​​​​​​The first interim results of ENZAMET have been reported by an Australian-led team

Taking enzalutamide improves overall survival and progression-free survival in men with hormone-sensitive metastatic prostate cancer compared with standard antiandrogen therapies, report Australian researchers.

Model illustrating prostate cancer

The first interim results of the ENZAMET trial show that men on enzalutamide are 33% less likely to have died than men on standard therapy after a median of 34 months’ follow-up.

Overall survival at three years was 80% in the enzalutamide group and 72% in the standard care group.